Deutsche Bank’s Atossa Therapeutics ATOS Stock Holding History

Deutsche Bank’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,828	Closed	-$90K	–	4129
2022 Q1	$90K	Buy	4,828 +92	+2%	+$1.87K	﹤0.01%	3617
2021 Q4	$114K	Sell	4,736 -3,781	-44%	-$138K	﹤0.01%	3647
2021 Q3	$416K	Buy	8,517 +3,887	+84%	+$226K	﹤0.01%	3166
2021 Q2	$439K	Buy	+4,630	New	+$245K	﹤0.01%	3297
2020 Q4	–	Sell	-294	Closed	-$11K	–	4405
2020 Q3	$11K	Buy	+294	New	+$14.1K	﹤0.01%	4187
2020 Q1	–	Sell	-426	Closed	-$10K	–	4326
2019 Q4	$10K	Buy	+426	New	+$10K	﹤0.01%	4481
2019 Q3	–	Sell	-20	Closed	–	–	4869
2019 Q2	$0	Buy	+20	New	+$801	﹤0.01%	5277
2018 Q3	–	Sell	-73	Closed	-$2K	–	5342
2018 Q2	$2K	Buy	+73	New	+$3.92K	﹤0.01%	5305
2018 Q1	–	Hold	0	–	–	–	5381
2017 Q4	–	Hold	0	–	–	–	4988
2017 Q3	–	Hold	0	–	–	–	4866
2017 Q2	–	Hold	0	–	–	–	4924
2017 Q1	–	Sell	-2	Closed	-$511	–	4899
2016 Q4	$0	Buy	+2	New	+$624	﹤0.01%	4902
2016 Q3	–	Hold	0	–	–	–	4900
2016 Q1	–	Sell	-13	Closed	-$12K	–	5139
2015 Q4	$11K	Buy	+13	New	+$20K	﹤0.01%	4897

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank's ATOS Position: Q2 2022 in Review

Deutsche Bank sold out of Atossa Therapeutics (ATOS) in Q2 2022, closing a stake of 4,828 shares — an estimated $90K sold.

Deutsche Bank first reported a position in ATOS in Q4 2015 and held it in 10 quarters. The position peaked at $439K in Q2 2021. 73 funds tracked by Wall St. Rank hold ATOS as of Q2 2022.

Deutsche Bank reported no remaining Atossa Therapeutics position as of Q2 2022 after selling out during the quarter.
Deutsche Bank sold 4,828 Atossa Therapeutics shares in Q2 2022, an estimated $90K.
Deutsche Bank first reported a position in Atossa Therapeutics in Q4 2015 and held it in 10 quarters.
Deutsche Bank's Atossa Therapeutics position peaked at $439K in Q2 2021.
73 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.